Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717315 | 0.86 | HSD11B1 (0.54) | SIGMAR1HRH3EPHX2EPHX1CYP1A2 | |
| SCHEMBL3159471 | 0.84 | CHRM3 (0.46) | HRH3CYP1A2CHRM3CHRM2CHRM1 | |
| SCHEMBL14167078 | 0.83 | CYP1A2 (0.43) | HRH3CYP1A2CHRM3CHRM2CHRM1 | |
| SCHEMBL24475418 | 0.81 | HRH3 (0.46) | SIGMAR1HRH3CHRM3 | |
| SCHEMBL23134532 | 0.81 | LMNA (0.40) | HRH3LMNA | |
| SCHEMBL25075241 | 0.81 | PIK3CD (0.40) | SIGMAR1CYP1A2CHRM3TDP1 | |
| SCHEMBL7484330 | 0.81 | L3MBTL1 (0.44) | HRH3CYP1A2CHRM3CHRM2CHRM1 | |
| SCHEMBL12506852 | 0.80 | CHRM5 (0.52) | MAPTLMNAPOLB | |
| SCHEMBL24865977 | 0.80 | HSD11B1 (0.51) | SIGMAR1CYP1A2CHRM3MAPTHSD11B1 | |
| SCHEMBL3159388 | 0.80 | HPGD (0.58) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | SIGMAR1 4269/4885HRH3 3443/4885EPHX2 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.